Seyedtaghi Takyar, PhD
Critical Care Medicine · New Haven, CTNPI 1558527424
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Rigel Pharmaceuticals, Inc.. That places this record below the midpoint for critical care medicine clinicians in CT, where the typical reported total is $271.
Across 2 payments — averaging $47.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rigel Pharmaceuticals, Inc.$96
Across 7 payments — averaging $47,718 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$334K
What the payments were for
- Food & beverage$96100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rigel Pharmaceuticals, Inc. | 2 | $96 |
How this compares
$96 in reported general payments places this provider in the 30th percentile of 51 critical care medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $35,868 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $19,786 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $12,610 |
| Spiriva RespimatTiotropium Bromide | 17 | $10,438 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $6,811 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $522 |
| Fluticasone Propionate | 32 | $243 |
| Azelastine Hcl | 11 | $200 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in New Haven
- Roland El GhazalNew Haven$19K
- Akhil KhoslaNew Haven$12K
- Andrew NotarianniNew Haven$4K
- Adel Bassily-MarcusNew Haven$4K
- Shahrukh ArifNew Haven$4K
- Mubdiul AliNew Haven$3K
- Laura NiklasonNew Haven$2K
- Jennifer PersioNew Haven$2K
- Harinder RanaNew Haven$612
- Ghaith AbdulkarimNew Haven$148
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.